These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 32591471

  • 1. CSF biomarkers in Olmsted County: Evidence of 2 subclasses and associations with demographics.
    Van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, Batrla-Utermann R, Dyer RB, Algeciras-Schimnich A, Knopman DS, Jack CR, Petersen RC.
    Neurology; 2020 Jul 21; 95(3):e256-e267. PubMed ID: 32591471
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 21; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 3. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.
    Alzheimers Res Ther; 2019 Dec 05; 11(1):99. PubMed ID: 31805990
    [Abstract] [Full Text] [Related]

  • 4. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype.
    Babapour Mofrad R, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, Teunissen CE.
    Neurology; 2020 Oct 27; 95(17):e2378-e2388. PubMed ID: 32788242
    [Abstract] [Full Text] [Related]

  • 5. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
    He B, Wang L, Xu B, Zhang Y, Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2021 May 29; 754():135765. PubMed ID: 33667602
    [Abstract] [Full Text] [Related]

  • 6. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative.
    J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262
    [Abstract] [Full Text] [Related]

  • 7. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A, Reimand J, Teunissen CE, Zwan M, Windhorst AD, Boellaard R, van der Flier WM, Scheltens P, van Berckel BNM, Bouwman F, Ossenkoppele R.
    Alzheimers Res Ther; 2019 Sep 12; 11(1):78. PubMed ID: 31511058
    [Abstract] [Full Text] [Related]

  • 8. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.
    JAMA Neurol; 2017 Dec 01; 74(12):1492-1501. PubMed ID: 29114726
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
    Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN.
    Alzheimers Res Ther; 2016 Apr 27; 8(1):17. PubMed ID: 27121148
    [Abstract] [Full Text] [Related]

  • 10. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.
    Arch Neurol; 1998 Jul 27; 55(7):937-45. PubMed ID: 9678311
    [Abstract] [Full Text] [Related]

  • 11. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
    Kern S, Syrjanen JA, Blennow K, Zetterberg H, Skoog I, Waern M, Hagen CE, van Harten AC, Knopman DS, Jack CR, Petersen RC, Mielke MM.
    JAMA Neurol; 2019 Feb 01; 76(2):187-193. PubMed ID: 30419087
    [Abstract] [Full Text] [Related]

  • 12. Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia.
    Hosseini AA, Brown T, Mannino L, Gran B, Junaid K, Mukaetova-Ladinska EB.
    J Alzheimers Dis; 2022 Feb 01; 87(2):771-780. PubMed ID: 35404281
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer's Disease Neuroimaging Initiative, Minthon L, Blennow K, Olsson M, Hansson O, Swedish BioFINDER Study Group.
    Neurology; 2015 Oct 06; 85(14):1240-9. PubMed ID: 26354982
    [Abstract] [Full Text] [Related]

  • 16. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR, Schellenberg GD, Wang LS, Alzheimer's Disease Neuroimaging Initiative.
    BMC Neurol; 2010 Oct 08; 10():90. PubMed ID: 20932310
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Oct 08; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q, Ni M, Gao F, Dai LB, Lv XY, Zhang YF, Shi Q, Zhu XX, Xie JK, Shen Y, Wang SC.
    ACS Chem Neurosci; 2022 May 18; 13(10):1558-1565. PubMed ID: 35476397
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
    Jung NY, Kim ES, Kim HS, Jeon S, Lee MJ, Pak K, Lee JH, Lee YM, Lee K, Shin JH, Ko JK, Lee JM, Yoon JA, Hwang C, Choi KU, Lee EC, Seong JK, Huh GY, Kim DS, Kim EJ.
    J Alzheimers Dis; 2020 May 18; 74(2):473-490. PubMed ID: 32039853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.